About Reforgene
Reforgene Medicine is one of China’s leading innovative gene editing drug companies. Driven by gene editing technology, it is dedicated to the birth of novel medicines. Reforgene has a high-caliber team that applied gene editing to the treatment of genetic diseases at an early stage internationally, and has accumulated pioneering achievements across multiple indications including hematology, cardiovascular and metabolic diseases, and infectious diseases. The company has built strong technical capabilities in gene editing tool innovation, drug development strategy, novel animal model construction, and multi-level efficacy and safety assessment, and operates both in vivo and ex vivo gene editing drug platforms. Reforgene’s mission is to deliver accessible, curative medicines for patients with serious diseases through innovative genetic technologies. The company has pipeline programs in genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world’s first cure of an alpha-thalassemia patient.
Our Mission
Developing curative medicines for serious diseases.
Reforgene Medicine
